Database : MEDLINE
Search on : Drug and Hypersensitivity and Syndrome [Words]
References found : 6719 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 672 go to page                         

  1 / 6719 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29515281
[Au] Autor:Pai S; Munshi R; Nayak C
[Ad] Address:Department of Clinical Pharmacology, TN Medical College and BYL Nair Charitable Hospital, Mumbai, Maharashtra, India.
[Ti] Title:Fatal dapsone hypersensitivity syndrome with hypothyroidism and steroid-induced diabetes mellitus.
[So] Source:Indian J Pharmacol;49(5):396-398, 2017 Sep-Oct.
[Is] ISSN:1998-3751
[Cp] Country of publication:India
[La] Language:eng
[Ab] Abstract:Dapsone has been part of the World Health Organization multidrug therapy for the treatment of leprosy. While it has been efficacious in the management of leprosy, there are many patients who develop adverse drug reactions to the drug including life-threatening reactions such as dapsone hypersensitivity syndrome (DHS). We report a case of a patient who was prescribed dapsone as part of multidrug therapy for leprosy following which she developed DHS. Her condition worsened after tapering the oral steroids given to manage the DHS, and she was detected to have hypothyroidism. She developed diabetes mellitus and succumbed to septic shock.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180311
[Lr] Last revision date:180311
[St] Status:In-Data-Review
[do] DOI:10.4103/ijp.IJP_764_16

  2 / 6719 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29519170
[Au] Autor:Behera SK; Das S; Xavier AS; Selvarajan S
[Ad] Address:a Department of Clinical Pharmacology , Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) , Puducherry , India.
[Ti] Title:DRESS syndrome: a detailed insight.
[So] Source:Hosp Pract (1995);, 2018 Mar 08.
[Is] ISSN:2154-8331
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a serious and potentially fatal adverse effect to therapeutic medications. The incidence of this condition varies among different ethnicities because of the difference in the genetic makeup. Though fever, rash and eosinophilia are essential features for the diagnosis of this syndrome, these vary from patient to patient along with the involvement of various organs such as liver, kidney, lungs, pancreas, etc. Some of the atypical features are dysphagia, agranulocytosis, and chylous ascites. Phenytoin, phenobarbitone, carbamazepine, and allopurinol are the most common drugs responsible for developing this syndrome, although the list is fairly long. Among the criteria used for the diagnosis of DRESS syndrome, European Registry of Severe Cutaneous Adverse Reactions to Drugs and Collection of Biological Samples (RegiSCAR) criteria is the most commonly used one. The management of this syndrome involves early removal of the causative agent and treatment with anti-histamines and emollients in the mild form, corticosteroids in the moderate form and plasmapheresis in the severe form along with other alternatives drugs. Healthcare professionals should be more vigilant about the early manifestations of this syndrome, as early diagnosis and treatment improve outcomes considerably.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher
[do] DOI:10.1080/21548331.2018.1451205

  3 / 6719 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29516901
[Au] Autor:Chen X; Wang S; Li L
[Ad] Address:Department of Dermatology, West China Hospital of Sichuan University, Chengdu, People's Republic of China.
[Ti] Title:A case of drug-induced hypersensitivity syndrome induced by icotinib managed by intravenous immunoglobulin and systemic corticosteroids.
[So] Source:Indian J Dermatol Venereol Leprol;, 2018 Mar 08.
[Is] ISSN:0973-3922
[Cp] Country of publication:India
[La] Language:eng
[Pt] Publication type:LETTER
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher
[do] DOI:10.4103/ijdvl.IJDVL_490_17

  4 / 6719 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29495100
[Au] Autor:Fabisiak A; Sobocinska M; Kamysz E; Fichna J; Zielinska M
[Ad] Address:Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.
[Ti] Title:Antinociceptive potency of enkephalins and enkephalinase inhibitors in the mouse model of colorectal distension - proof of concept.
[So] Source:Chem Biol Drug Des;, 2018 Mar 01.
[Is] ISSN:1747-0285
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Irritable bowel syndrome (IBS) is a chronic disease characterized by abdominal pain and changes in bowel habits. Patients with IBS comprise a significant portion of attendants at the outpatient clinics. Targeting intestinal opioid receptors was found successful in alleviating pain and diarrhea - two major symptoms of IBS. In this study we aimed to evaluate a novel potential pharmacological option: the use of enkephalinase inhibitors in therapy of visceral pain occurring in the course of IBS. We thus assessed the antinociceptive efficacy of enkephalins: Leu-enkephalin and Met-enkephalin, and enkephalinase inhibitors: opiorphin and sialorphin in the mouse model of visceral pain induced by colorectal distension.Leu-enkephalin, Met-enkephalin and sialorphin, but not opiorphin, at the dose of 1 mg/kg injected subcutaneously potently decreased the visceromotor response to colon distension as compared to control. To conclude, enkephalinase inhibitors are worth being considered as potential therapeutics in patients with chronic abdominal pain and/or changed bowel habits, i.e. suffering from IBS. This article is protected by copyright. All rights reserved.
[Pt] Publication type:LETTER
[Em] Entry month:1803
[Cu] Class update date: 180301
[Lr] Last revision date:180301
[St] Status:Publisher
[do] DOI:10.1111/cbdd.13186

  5 / 6719 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27779084
[Au] Autor:Bonadonna P; Bonifacio M; Zanotti R
[Ad] Address:Allergy Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Piazzale Stefani 1, 37126, Verona, Italy.
[Ti] Title:Mast Cell Disorders In Drug Hypersensitivity.
[So] Source:Curr Pharm Des;22(45):6862-6869, 2016.
[Is] ISSN:1873-4286
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:Mastocytosis is a clonal disease characterized by proliferation and accumulation of mast cells (MC) in different tissues, preferentially skin and bone marrow, leading to a wide variety of clinical manifestations, mainly caused by the inappropriate release of MC mediators. As a consequence, patients with mastocytosis may experience symptoms due to massive MC activation and release of mediators. Anaphylaxis is the most frequent manifestation of this phenomenon. Drugs are possible triggers of anaphylaxis in patients with mastocytosis, even though the association between mastocytosis and drug anaphylaxis does not appear to be as strong as anaphylaxis after hymenoptera sting; nevertheless, MC disorders might be ruled out in cases of severe systemic reactions to drugs. Moreover, the risk of perioperative anaphylaxis in adults appears high, mainly in patients with indolent systemic mastocytosis regardless of skin involvement. Such risk is probably lower in patients who have never experienced anaphylaxis and/or have tolerated previous general anaesthesia. However, data published about drug anaphylaxis in patients with MC disorders are scanty and currently it is not possible to provide clear recommendations.
[Mh] MeSH terms primary: Anaphylaxis/immunology
Drug Hypersensitivity/immunology
Mast Cells/immunology
Mast Cells/pathology
Mastocytosis/pathology
[Mh] MeSH terms secundary: Anaphylaxis/diagnosis
Anaphylaxis/epidemiology
Drug Hypersensitivity/diagnosis
Drug Hypersensitivity/epidemiology
Humans
Mast Cells/drug effects
Mastocytosis/diagnosis
Mastocytosis/epidemiology
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1712
[Cu] Class update date: 180227
[Lr] Last revision date:180227
[Js] Journal subset:IM
[Da] Date of entry for processing:161026
[St] Status:MEDLINE
[do] DOI:10.2174/1381612822666160928121857

  6 / 6719 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27779083
[Au] Autor:Paulmann M; Mockenhaupt M
[Ti] Title:Severe Drug Hypersensitivity Reactions: Clinical Pattern, Diagnosis, Etiology and Therapeutic Options.
[So] Source:Curr Pharm Des;22(45):6852-6861, 2016.
[Is] ISSN:1873-4286
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:Severe cutaneous adverse reactions (SCAR) are known for a high morbidity and mortality. They may be life-threatening for the affected patient and difficult to accomplish for the patient's family and the treating physician. Such conditions include not only bullous reactions like toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS), but also acute generalized exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms (DRESS). Since clinical pattern, etiology, prognosis and treatment differ among these severe skin reactions, a clear diagnosis based on a comprehensive clinical examination, skin biopsy, and specific laboratory tests is necessary. Because most of these reactions are caused by drug intake, a thorough history of medication use has to be obtained. However, there are cases with an infectious or idiopathic cause. In any case it is crucial to identify the most likely cause and rapidly discontinue the inducing agent, if a drug cause is suspected. This is associated with the patient`s prognosis which is often poor for bullous reaction. In addition, patient's age, underlying conditions, and the extent of skin detachment play a major role in terms of prognosis. Severe cutaneous adverse reactions are T-cell-mediated reactions, and certain alleles of human leukocyte antigens (HLA) are involved in the activation of T-cells with cytotoxic effect. The therapeutic options depend on the clinical diagnosis. For all reactions a symptomatic and adequate supportive therapy is necessary, in some cases a systemic immunomodulating therapy can be useful.
[Mh] MeSH terms primary: Drug Hypersensitivity
Stevens-Johnson Syndrome
[Mh] MeSH terms secundary: Drug Hypersensitivity/diagnosis
Drug Hypersensitivity/etiology
Drug Hypersensitivity/therapy
Humans
Stevens-Johnson Syndrome/diagnosis
Stevens-Johnson Syndrome/etiology
Stevens-Johnson Syndrome/therapy
[Pt] Publication type:JOURNAL ARTICLE; REVIEW; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Entry month:1712
[Cu] Class update date: 180227
[Lr] Last revision date:180227
[Js] Journal subset:IM
[Da] Date of entry for processing:161026
[St] Status:MEDLINE
[do] DOI:10.2174/1381612822666160928125152

  7 / 6719 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29475455
[Au] Autor:Anandabaskaran S; Ho V
[Ad] Address:Department of Medicine, Campbelltown Public Hospital, Campbelltown, NSW, 2560, Australia. sulakchanan.anandabaskaran@health.nsw.gov.au.
[Ti] Title:Rapid bupropion-induced hepatotoxicity: a case report and review of the literature.
[So] Source:J Med Case Rep;12(1):46, 2018 Feb 24.
[Is] ISSN:1752-1947
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Bupropion is an antidepressant that is also used as a non-nicotine method to aid in smoking cessation. Bupropion-induced hepatotoxicity is quoted to affect between 0.1% and 1% of treated patients with either a hepatocellular and/or cholestatic pattern of damage. The mechanism of damage is considered to be predominantly immune-mediated with the presence of a hypersensitivity syndrome (fever, rash, eosinophilia, autoantibodies) and a short latency period (1-6 weeks). We believe our reporting of this case to the already existing small list of only seven cases in the world literature will help practicing physicians to deal with the diagnostic and management dilemmas that bupropion-induced hepatotoxicity brings. CASE PRESENTATION: A 50-year-old Caucasian woman presented to our hospital with significant derangement of liver transaminases after 6 days of bupropion treatment for smoking cessation. The patient's other medications were considered unlikely to be the cause of the hepatotoxicity and were therefore continued. The patient's liver function tests normalized on withdrawal of bupropion, confirming that bupropion was the probable cause of the patient's hepatotoxicity. CONCLUSIONS: We conclude that hepatotoxicity is a rare adverse effect of bupropion use, but physicians should be aware of the possibility of this potentially serious clinical picture of drug-induced hepatotoxicity with varied clinical presentation and prognosis.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180224
[Lr] Last revision date:180224
[St] Status:In-Process
[do] DOI:10.1186/s13256-018-1563-9

  8 / 6719 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29368897
[Au] Autor:Suástegui-Rodríguez I; Campos-Jiménez KI; Domínguez-Cherit J; Méndez-Flores S
[Ad] Address:Departamento de Dermatología, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Ciudad de México, México.
[Ti] Title:Reacciones cutáneas adversas a medicamentos. [Adverse cutaneous reactions to drugs].
[So] Source:Rev Med Inst Mex Seguro Soc;56(1):64-70, 2018 Jan-Feb.
[Is] ISSN:2448-5667
[Cp] Country of publication:Mexico
[La] Language:spa
[Ab] Abstract:Adverse cutaneous reactions to drugs are any undesirable change in the structure or function of the skin. These are among the adverse side effects to common drugs. The most commonly implicated drugs are antibiotics and anticonvulsants. Cutaneous clinical manifestations are diverse ranging from mild or moderate reactions, such as urticaria and maculopapular rash, to severe cutaneous adverse reactions (SCAR), which are known due to their high morbidity and mortality (among these: Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS). The clinical pattern, etiology, prognosis and treatment differ among these skin reactions, which is why it is necessary a clear diagnosis based on a comprehensive clinical examination, skin biopsy, and specific laboratory tests. The therapeutic options depend on the clinical diagnosis. For all reactions, a symptomatic and adequate supportive therapy is necessary; in some cases, a systemic immunomodulatory therapy can be useful.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[St] Status:In-Process

  9 / 6719 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29466850
[Au] Autor:Yang MS; Kim JY; Kang MG; Lee SY; Jung JW; Cho SH; Min KU; Kang HR
[Ad] Address:Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea.
[Ti] Title:Direct costs of severe cutaneous adverse reactions in a tertiary hospital in Korea.
[So] Source:Korean J Intern Med;, 2018 Feb 23.
[Is] ISSN:2005-6648
[Cp] Country of publication:Korea (South)
[La] Language:eng
[Ab] Abstract:Background/Aims: There are only a few reports on the direct costs of severe cutaneous adverse reactions (SCARs), including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), despite the tremendous negative impact these reactions can have on patients. We estimated the direct costs of treating SCARs. Methods: Patients admitted to a tertiary teaching hospital for the treatment of SCARs from January 1, 2005 to December 31, 2010 were included. Patients who had experienced SCARs during their admission for other medical conditions were excluded. The direct costs of hospitalization and outpatient department visits were collected. Inpatient and outpatient care costs were calculated, and factors affecting inpatient care costs were analyzed. Results: The total healthcare cost for the management of 73 SCAR patients (36 with DRESS, 21 with SJS, and 16 with TEN) was 752,067 US dollars (USD). Most of the costs were spent on inpatient care (703,832 USD). The median inpatient care cost per person was 3,720 (range, 1,133 to 107,490) USD for DRESS, 4,457 (range, 1,224 to 21,428) USD for SJS, and 8,061 (range, 1,127 to 52,220) USD for TEN. Longer hospitalization significantly increased the inpatient care costs of the patients with DRESS (by 428 USD [range, 395 to 461] per day). Longer hospitalization and death significantly increased the inpatient care costs of the patients with SJS/TEN (179 USD [range, 148 to 210] per day and an additional 14,425 USD [range, 9,513 to 19,337] for the deceased). Conclusions: The management of SCARs required considerable direct medical costs. SCARs are not only a health problem but also a significant financial burden for the affected individuals.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[St] Status:Publisher
[do] DOI:10.3904/kjim.2015.365

  10 / 6719 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29432504
[Au] Autor:Mehrholz D; Urban AE; Herstowska M; Nowicki R; Cubala W; Baranska-Rybak W
[Ad] Address:Klinika Dermatologii, Wenerologii i Alergologii Gdanskiego Uniwersytetu Medycznego.
[Ti] Title:Analiza retrospektywna DRESS ­ reakcji polekowej z eozynofilia i powiklaniami narzadowymi. A retrospective study of DRESS - drug reaction with eosinophilia and systemic symptoms.
[So] Source:Psychiatr Pol;51(6):1079-1093, 2017 Dec 30.
[Is] ISSN:2391-5854
[Cp] Country of publication:Poland
[La] Language:eng; pol
[Ab] Abstract:OBJECTIVES: DRESS (drug reaction with eosinophilia and systemic syndrome) is qualified as hypersensitivity after drug reaction. This syndrome may occur due to any medication intake. There are three main groups of symptoms defining DRESS: skin lesions, hematological abnormalities and internal organ involvement. METHODS: A retrospective study was performed on a group of 261 patients with drug reactions hospitalized in the Clinic of Dermatology from 2004 until 2017. RESULTS: There were ten cases of DRESS of 261 hypersensitivity drug reactions observed in the Clinic. The drug which most frequently caused DRESS in the studied group was carbamazepine - six patients (60%). Lamotrigine was the cause of DRESS in two cases, oxycarbamazepine in one patient and dexketoprofen in one patient. The skin lesion was present in 100% patients. Mainly it was coalescing hemorrhagic rash accompanied by face edema. Eosinophilia was noticed in 80% of patients and the presence of atypical lymphocytes - in 40%. The main infiltrate organ was liver in 8 cases. CONCLUSIONS: DRESS diagnosis should be taken into consideration especially in patients treated eith antiepileptic drugs. Early diagnosis and drug discontinuation can contribute to preventing serious complications of DRESS.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180212
[Lr] Last revision date:180212
[St] Status:In-Process


page 1 of 672 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information